Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Clinical trial NCT06930352 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06930352
- Sponsor
- Uma Borate
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-10
- Primary completion
- 2027-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.